Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

"October's healthy sales boost is a welcome development for buyers and sellers alike,” said Baldev Gill, CEO of the Fraser ...

BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...

The program has a formidable line-up of speakers and an extensive program to create a meaningful dialogue on the biomarkers of aging. The 2-day program aims to build on last year’s inaugural ...

The dramatically upsized IPO ties into an increasingly buoyant biotech financing environment, with a string of upsized ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MAI Capital Management LLC, a registered investment adviser focused on investment and financial planning for high-net-worth individuals and families, has bought Hyperion Partners. Headquartered in ...

Shares of Sangamo Therapeutics (SGMO: NASDAQ) surged 69% this past week after the genetic medicines developer announced regulatory progress in its quest to develop its wholly owned gene therapy ...

Robust debuts by drug developers Bicara Therapeutics , MBX Biosciences, BioAge Labs and Upstream Bio are also encouraging potential candidates in the sector to move ahead with their listings. Septerna ...